New York, USA, Jan. 28, 2025 (GLOBE NEWSWIRE) -- Pulmonary Fibrosis Clinical Trial Pipeline Appears Robust With 110+ Key Pharma Companies Actively Working in the Therapeutics Segment ...

Analyst Patrick Trucchio from H.C. Wainwright reiterated a Buy rating on Silence Therapeutics (SLN – Research Report) and keeping the price target at $75.00. Patrick Trucchio has given his Buy ...

In response to the epetraborole setback, AN2 Therapeutics has swiftly pivoted its strategy to focus on its broader platform technology and other pipeline candidates. This shift demonstrates the ...

收市後：January 31 at 4:59:14 PM EST Loading Chart for ABEO ...

The company currently has 8 candidates in the pipeline, of which 2 already in clinical trials. CRISPR Therapeutics has also collaborated with the company ViaCyte to improve its product. ViaCyte is ...

$500 million upfront and a total deal value of up to $5 billion sounds like a deal made by a top-tier pharma company – but, in fact, it comes from diminutive biotech Summit Therapeutics. The ...

Dyne Therapeutics Inc. 4.43% $1.38B ...

Sanofi S.A. Part Cert-1.97% €8.03M ...

Kate Therapeutics' pipeline is still in the preclinical stage of development but includes candidates for DMD, facioscapulohumeral dystrophy (FSHD), and myotonic dystrophy type 1 (DM1), as well as ...